BIOMAT Database Logo BIOMAT Database Logo

High-dose Ara-C as a single-agent consolidation therapy in childhood acute myelogenous leukemia. 1990

S O Lie, and G Berglund, and G Gustafsson, and G Jonmundsson, and M Siimes, and M Yssing
Dept. of Pediatrics, Rikshospitalet, Oslo, Norway.

UI MeSH Term Description Entries
D007055 Iceland A country in northern Europe, an island between the Greenland Sea and the North Atlantic Ocean, northwest of the United Kingdom. The capital is Reykjavik.
D007223 Infant A child between 1 and 23 months of age. Infants
D007231 Infant, Newborn An infant during the first 28 days after birth. Neonate,Newborns,Infants, Newborn,Neonates,Newborn,Newborn Infant,Newborn Infants
D011289 Preleukemia Conditions in which the abnormalities in the peripheral blood or bone marrow represent the early manifestations of acute leukemia, but in which the changes are not of sufficient magnitude or specificity to permit a diagnosis of acute leukemia by the usual clinical criteria. Preleukemias
D012074 Remission Induction Therapeutic act or process that initiates a response to a complete or partial remission level. Induction of Remission,Induction, Remission,Inductions, Remission,Remission Inductions
D002648 Child A person 6 to 12 years of age. An individual 2 to 5 years old is CHILD, PRESCHOOL. Children
D002675 Child, Preschool A child between the ages of 2 and 5. Children, Preschool,Preschool Child,Preschool Children
D003131 Combined Modality Therapy The treatment of a disease or condition by several different means simultaneously or sequentially. Chemoimmunotherapy, RADIOIMMUNOTHERAPY, chemoradiotherapy, cryochemotherapy, and SALVAGE THERAPY are seen most frequently, but their combinations with each other and surgery are also used. Multimodal Treatment,Therapy, Combined Modality,Combined Modality Therapies,Modality Therapies, Combined,Modality Therapy, Combined,Multimodal Treatments,Therapies, Combined Modality,Treatment, Multimodal,Treatments, Multimodal
D003430 Cross-Sectional Studies Studies in which the presence or absence of disease or other health-related variables are determined in each member of the study population or in a representative sample at one particular time. This contrasts with LONGITUDINAL STUDIES which are followed over a period of time. Disease Frequency Surveys,Prevalence Studies,Analysis, Cross-Sectional,Cross Sectional Analysis,Cross-Sectional Survey,Surveys, Disease Frequency,Analyses, Cross Sectional,Analyses, Cross-Sectional,Analysis, Cross Sectional,Cross Sectional Analyses,Cross Sectional Studies,Cross Sectional Survey,Cross-Sectional Analyses,Cross-Sectional Analysis,Cross-Sectional Study,Cross-Sectional Surveys,Disease Frequency Survey,Prevalence Study,Studies, Cross-Sectional,Studies, Prevalence,Study, Cross-Sectional,Study, Prevalence,Survey, Cross-Sectional,Survey, Disease Frequency,Surveys, Cross-Sectional
D003561 Cytarabine A pyrimidine nucleoside analog that is used mainly in the treatment of leukemia, especially acute non-lymphoblastic leukemia. Cytarabine is an antimetabolite antineoplastic agent that inhibits the synthesis of DNA. Its actions are specific for the S phase of the cell cycle. It also has antiviral and immunosuppressant properties. (From Martindale, The Extra Pharmacopoeia, 30th ed, p472) Ara-C,Arabinofuranosylcytosine,Arabinosylcytosine,Cytosine Arabinoside,Aracytidine,Aracytine,Cytarabine Hydrochloride,Cytonal,Cytosar,Cytosar-U,beta-Ara C,Ara C,Arabinoside, Cytosine,Cytosar U,beta Ara C

Related Publications

S O Lie, and G Berglund, and G Gustafsson, and G Jonmundsson, and M Siimes, and M Yssing
Low-dose ara-C therapy for acute myelogenous leukemia in elderly patients.
January 1989, Leukemia,
S O Lie, and G Berglund, and G Gustafsson, and G Jonmundsson, and M Siimes, and M Yssing
Intermediate-dose Ara-C/m-AMSA for remission induction and high-dose Ara-C/m-AMSA for intensive consolidation in relapsed and refractory adult acute myelogenous leukemia (AML).
January 1989, Anticancer research,
S O Lie, and G Berglund, and G Gustafsson, and G Jonmundsson, and M Siimes, and M Yssing
Treatment of acute myelogenous leukemia in the older patient with attenuated high-dose ara-C.
April 1998, American journal of clinical oncology,
S O Lie, and G Berglund, and G Gustafsson, and G Jonmundsson, and M Siimes, and M Yssing
Low-dose cytosine arabinoside (Ara-C) therapy in the myelodysplastic syndromes and acute myelogenous leukemia.
January 1987, Haematologica,
S O Lie, and G Berglund, and G Gustafsson, and G Jonmundsson, and M Siimes, and M Yssing
[High-dose Ara-C treatment of acute leukemia].
May 1986, Gan to kagaku ryoho. Cancer & chemotherapy,
S O Lie, and G Berglund, and G Gustafsson, and G Jonmundsson, and M Siimes, and M Yssing
Prolonged high dose ARA-C infusions in acute leukemia.
May 1988, Leukemia,
S O Lie, and G Berglund, and G Gustafsson, and G Jonmundsson, and M Siimes, and M Yssing
Modulation of cytosine arabinoside (ara-C) and high-dose ara-C in acute leukemia.
June 1985, Seminars in oncology,
S O Lie, and G Berglund, and G Gustafsson, and G Jonmundsson, and M Siimes, and M Yssing
Core binding factor acute myeloid leukemia (CBF-AML): is high-dose Ara-C (HDAC) consolidation as effective as you think?
March 2009, Current opinion in hematology,
S O Lie, and G Berglund, and G Gustafsson, and G Jonmundsson, and M Siimes, and M Yssing
A randomized comparison of modified intermediate-dose Ara-C versus high-dose ara-c in post-remission therapy for acute myeloid leukemia.
February 2012, Anticancer research,
S O Lie, and G Berglund, and G Gustafsson, and G Jonmundsson, and M Siimes, and M Yssing
Subacute pulmonary failure complicating therapy with high-dose Ara-C in acute leukemia.
November 1985, Cancer,
Copied contents to your clipboard!